Sunovion is putting a ton of resources behind Latuda. They were smart in hiring mostly people who were currently employed with AZ, Janssen, Lily, and BMS/OAPI reps. Those are the 4 most prescribed atypicals so they have put a veteran and experienced salesforce together to launch the drug. I also heard that Andrei Pikalov is with them now which is a major coup for them as well. I think any OAPI rep that left is smart. OAPI has been in a downward spiral for a couple of years now thanks to your current leadership. Sunovion is exactly what OAPI use to be - a smaller, privately owned Japanese pharmaceutical company with a robust pipeline and a management team that doesn't have an identity crisis. Plus they have the financial backing of Sepracor as well. Who wouldn't want to leave OAPI for that environment? Oh yeah, bottom feeders wouldn't want to leave.